The
original antigenic sin has made fighting diseases really difficult. Shutterstock
|
Dr
Wilfred Ndifon has proposed a solution to a 70-year old immunological mystery
relating to the original antigenic sin. This complex problem has played havoc
with efforts to fight infectious diseases, particularly in places such as
Africa where people can suffer successive infections. Ndifon and Tolullah Oni
are two of 12 Next Einstein Forum Fellows working to solve major challenges in
health, education, big data and quantum theory using science, technology,
engineering and mathematics.
What is the original
antigenic sin?
The
original antigenic sin was first reported about 70 years ago by American
epidemiologist Thomas Francis Jr. But its underlying biological mechanisms are
still poorly understood.
This
much we know: the human body activates white blood cells to fight an infection.
When a new infection comes along the white blood cells are activated again. But
they are less effective at fighting the new agent. This makes the body much
less able to fight the new disease. This is what Thomas Francis described as
the original antigenic sin.
The
length of time over which original antigenic sin can occur depends on how long
the immune system’s memory of a previous infection lasts, which in turn depends
on the infecting pathogen. For pathogens like flu viruses, the immune system’s
memory can persist throughout an individual’s lifetime.
The
same problem arises when a person is treated with a vaccine to fight pathogen
A. When that person is infected by a related pathogen B, the vaccine focuses on
pathogen A making it less effective.
Why does this matter?
The
original antigenic sin makes fighting diseases really difficult. This is
because it reduces the effectiveness of vaccines. This happens because vaccines
preferentially reactivate previously activated white blood cells. So past
infections increase the risk for more severe future infections and for reduced
vaccine effectiveness.
This
risk is particularly high in sub-Saharan Africa where infections tend to occur
frequently. The risk is high in regions where infections occur frequently
simply because you need sequential infections with related pathogens in order
for original antigenic sin to manifest.
So,
the more infections there are, the more likely it is that the body’s defences
will be compromised by original antigenic sin. This is also pertinent in the
Northern Hemisphere where there are frequent sequential infections by related
variants of flu viruses. This creates an ideal environment for original
antigenic sin to manifest.
It
is also important in other parts of the world where flu is prevalent.
Scientists
have documented many instances of the original antigenic sin in humans, mice,
and other organisms.
It
has been beautifully illustrated in mice that were infected either with only
one variant of the flu virus or with that variant followed a month later by
another related variant. While the mice infected with only one variant were
able to completely control a subsequent infection with that variant, those that
were sequentially infected had about 10 000 times more virus in their lungs as a
result of original antigenic sin.
NEF
Fellow Wilfred Ndifon on how he solved 70 year old immunological problem.
Can you give a practical
example?
Imagine
for a minute that you have malaria.
The
immune system contains specialized white blood cells that are responsible for
protecting the body from pathogens which cause malaria.
When
the immune system is exposed to the pathogen, the pathogen is chopped into
pieces called antigens. Then it is loaded onto the surface of other white blood
cells. The white blood cells then become activated. They are then able to get
rid of the malaria.
A
small number of these white blood cells remain after the pathogen has been
eliminated. They stay behind to enable a swift response to any infection by the
same pathogen.
After
eliminating malaria, let’s imagine you are infected by a new variant of the
pathogen. Normally the body should unleash the same process. But this is not
always the case.
In
some cases, the white blood cells do not recognize the new pathogen. Instead,
they focus on the previous pathogen. An earlier theory suggested that this may
result from competition among certain white blood cells called B cells. In
immunology this is called the original antigenic sin.
So what’s the solution?
My
study introduced and confirmed an original theory using mathematics and
experimental data. My theory explains why original antigenic sin occurs. It is
also the first theory to explain how original antigenic sin can be alleviated
by a substance that is added to a vaccine to better activate the immune
system’s cells. What we call an adjuvant.
I
show that both original antigenic sin and its alleviation by adjuvants arise
from the activity of certain white blood cells called T regulatory cells.
T
regulatory cells activated by previous pathogens weaken certain white blood
cells' ability to load new pathogens onto their surface. This in turn causes
fewer white blood cells to become activated, thereby making it difficult for
the body to fight new pathogens and leading to original antigenic sin.
But
my theory predicts that adjuvants will reduce the inhibition of white blood
cell activation that is caused by T regulatory cells, thereby alleviating
original antigenic sin.
My
discovery opens up additional possibilities for preventing the destructive
health consequences of original antigenic sin. For example, it suggests how
original antigenic sin can be prevented from reducing a vaccine’s
effectiveness. This can be done by designing vaccines so that their components
better latch onto the surface of certain white blood cells.
This will counter the effect
of the T regulatory cells and make the immune system more effective at getting
rid of the pathogens targeted by the vaccine.
Wilfred Ndifon (Left)
Research
Chair with joint appointments at both the South African and the Ghanaian
centres of the African Institute for Mathematical Sciences. He is also
affiliated to the Department of Mathematical Sciences, Stellenbosch University.
Tolullah Oni (Right)
Senior Lecturer at the
School of Public Health and Family Medicine, University of Cape Town.
Originally published in The Conversation